Abstract:Abstract Background and objectiveIn recent years, a wide variety of immune checkpoint inhibitors (ICIs) is emerging and has shown long-lasting and significant efficacy in the treatment of various malignant tumors. However, about 10% of patients experience serious and even life-threatening immune-related adverse events (irAEs). Fully understanding the characteristics of toxic effects and biomarkers to predict irAEs is, therefore, of great interest. We aimed to retrospectively analyze the toxicity profile and predictors of irAEs, as well as the correlation between irAEs and clinical efficacy in patients with advanced pan-cancer who were treated with multi-type ICIs in real-world.MethodsWe retrospectively analyzed data from 105 patients with advanced pan-cancer who were treated with multi-type ICIs in the First Hospital of Jilin University from Jan 1, 2016 to Aug 1, 2020. We used logistic regression analyses to investigate associations between irAEs and clinical baseline characteristics, blood count parameters, and biochemical indicators during the treatment. Receiver-operating characteristic (ROC) curve was used to determine a cutoff value for parameters and area under the curve (AUC). Kaplan–Meier and cox multivariate regression analysis were performed to estimate the relationship of baseline characteristics and irAEs with progression-free survival (PFS) and overall survival (OS).ResultsWe found that lower relative lymphocyte count (RLC) (cutoff=0.285*10^9/L), higher albumin (ALB) (cutoff=39.05g/L) and higher absolute eosinophil count (AEC) (cutoff=0.175*10^9/L) were significantly associated with the occurrence of any irAEs, of which a higher AEC (cutoff=0.205*10^9/L) was strongly associated with skin-related irAEs (HR=0.163, p=0.004); And a higher lactate dehydrogenase (LDH) level (cutoff=237.5U/L) was an independent predictor of serious irAEs (HR=0.199, p=0.022). In the analysis of immune cell subgroup, lower absolute CD8+CD28- T cell count (HR=0.806; 95%CI: 0.643-1.011; p=0.062), a regulatory T lymphocytes, was associated with the occurrence of irAEs, although the difference was not statistically significant; And a higher percentage of CD19+ B cells were associated with the occurrence of serious irAEs and irAEs of grade ≥2 (p＜0.05). In addition, our study showed that patients with any grade irAE had a significantly better PFS (8.37 vs.3.77 months, HR=2.02, p=0.0038) and OS (24.77 vs.13.83 months, HR=1.78, p=0.029).ConclusionsThis retrospective study reported the clinical profile data of irAEs of unselected patients in the real world, and explored some parameters that may all be conventional, potentially predictable markers of the occurrence, type, or grade of irAEs in clinical practice. Evidence of a correlation between safety and efficacy may contribute to fully assess the risk-benefit ratio for patients treated with ICIs.

Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy

Development and Validation of a Risk-Prediction Model for Immune-Related Adverse Events in Patients with Non-Small-cell Lung Cancer Receiving PD-1/PD-L1 Inhibitors.

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors

Immunogenetic variations predict immune-related adverse events for PD-1/PD-L1 inhibitors.

Analysis of Toxicity Profile and Predictors of Immune Checkpoint Inhibitor-Related Adverse Events

B-384 Genetic Variations Predict Severe Immunotherapy-related Adverse Events for PD-1/PD-L1 Inhibitors

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events

Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors

1069P Potential Biomarkers for Predicting Severe Immune-Related Adverse Events During Checkpoint Immunotherapy: T Cell Receptor and Whole Exome Sequencing Findings from a Prospective Multicenter Study

Association of Immune-Related Adverse Events with Immune Checkpoint Inhibitor Efficacy in Pancancer.

Association between programmed death protein 1-related single-nucleotide polymorphisms and immune-related adverse events induced by programmed death protein 1 inhibitors-a pilot study

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma

Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

Analysis of Immune-Related Adverse Events and Its Correlation with Efficacy of Anti-Pd-1 Monotherapy in Advanced Non-Small Cell Lung Cancer

Biomarkers and risk factors for the early prediction of immune-related adverse events: a review.

Development of a predictive model for immune‐related adverse events in patients with cancer

Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors

Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer

Multi-omics Prediction of Immune-Related Adverse Events During Checkpoint Immunotherapy